AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RMD

FARRELL PETER C sold $228K of RMD

FARRELL PETER C sold 970 shares of RESMED INC (RMD) at $234.73 ($0.23M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FARRELL PETER C
Published Sep 4, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Neutral
high confidence
Mentioned
$RMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

Provides a primary source of insider sale data; limited trading relevance.

02

Market read

Small insider sale with minimal market impact.

03

What to watch

Potential upcoming earnings or product news may dominate price action.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-04

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$RMDNeutralHigh confidence
Context

Director Peter Farrell sold 970 shares of ResMed for $227,688 on 2026-09-02 via a 10b5‑1 plan.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The sale size is small relative to total float and insider holdings remain substantial.

Market effects

Sector

None significant for the medical device sector.

Regional

No regional effect.

Global

Limited to ResMed investors.

Counterpoint

What could challenge this read

Insider sale could signal concerns, but size is trivial.

Key entities

  • Company
    ResMed Inc.

    Medical device manufacturer.

  • Individual
    Peter Farrell

    Director of ResMed.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com